Abbott Laboratories Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Abbott Laboratories operates four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The quarter was defined by the completion of the Exact Sciences Corporation acquisition on March 23, 2026, for approximately $20.6 billion, significantly expanding Abbott's presence in the cancer diagnostics market.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $11,164 million | $10,358 million |
| Operating Earnings | $1,345 million | $1,693 million |
| Net Earnings | $1,077 million | $1,325 million |
| Diluted EPS | $0.61 | $0.76 |
| Gross Margin | 52.4% | 52.8% |
| Operating Cash Flow | $1,315 million | $1,417 million |
| Cash & Equivalents (End) | $6,803 million | $6,532 million |
| Total Debt (Current + Long-term) | $34,047 million | $12,929 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.8% year-over-year. Excluding foreign exchange, sales grew 3.8%, driven by Medical Devices (+8.1% organic) and Established Pharmaceutical Products (+9.0% organic). Nutritional Products declined 7.7% organically due to lower volumes.
- Profitability Decline: Operating earnings decreased 20.5% to $1.345 billion. This was primarily due to a $679 million increase in Selling, General, and Administrative (SG&A) expenses, largely attributed to the Exact Sciences acquisition integration and stock-based compensation ($321 million related to the acquisition).
- Balance Sheet Expansion: Total assets increased from $86.7 billion to $110.4 billion. Long-term debt surged from $9.9 billion to $29.6 billion following the issuance of $20.0 billion in new debt to fund the Exact Sciences acquisition. Goodwill increased by $11.4 billion to $35.2 billion.
- Cash Flow: Operating cash flow decreased slightly by $102 million. Investing activities showed a significant outflow of $20.3 billion, primarily for the acquisition. Financing activities generated $17.3 billion, driven by new debt issuance.
Outlook, Risks, and Management Commentary
- Acquisition Impact: The Exact Sciences acquisition added $96 million in net sales for the quarter. Pro forma results suggest the acquisition would have increased Q1 2025 sales to $11.1 billion but reduced earnings before taxes to $0.7 billion due to transaction costs and amortization.
- Segment Performance: Medical Devices saw double-digit organic growth in Rhythm Management, Electrophysiology, and Heart Failure. Diagnostic Products growth was offset by a 9.6% organic decline in Rapid and Molecular Diagnostics due to a weaker respiratory virus season.
- Legal and Tax Risks:
- NEC Litigation: Abbott faces ongoing lawsuits regarding infant formula and necrotizing enterocolitis (NEC). While Abbott prevailed in federal bellwether cases, state court outcomes vary. No reserve is recorded for these specific matters due to uncertainty, though a general legal accrual of $120 million exists.
- Tax Disputes: Abbott is contesting Statutory Notices of Deficiency (SNOD) from the IRS for tax years 2017–2020 totaling over $1.05 billion. Additionally, a $413 million tax assessment by Malaysian authorities was upheld by the Penang High Court; Abbott has appealed to the Court of Appeals.
- Capital Allocation: The company declared a quarterly dividend of $0.63 per share (up 6.8% YoY). Approximately $6.7 billion remains available under the $7 billion share repurchase program authorized in October 2024.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline for realizing synergies and the final purchase price allocation for Exact Sciences, which is currently preliminary.
- Debt Servicing: Assess the impact of the new $20 billion debt load on future interest expenses and credit ratings (currently A+/Aa3).
- Legal Exposure: Monitor the status of the NEC litigation appeals and the outcome of the Malaysian tax appeal, as these could result in material liabilities.
- Organic Growth Trends: Scrutinize the organic decline in Nutritional Products and Rapid/Molecular Diagnostics to determine if these are temporary market shifts or structural issues.
- Share-Based Compensation: Review the sustainability of SG&A expenses, noting the significant one-time stock compensation charge ($321 million) related to the Exact Sciences deal.